FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
CO015 | EVOLUTION OF ANTICOAGULANT THERAPY FOR CANCER-ASSOCIATED THROMBOSIS: THE START2 REGISTRY ONCO-VTE LONGITUDINAL STUDY M. Marchetti1|2, T. Zollner1|2, O.C. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo, Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Roma, Roma, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Torino, Italy; 7Department of Medicine, University of Padua, Padova, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Roma, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
156PDF: 25 -
CS04 | Association between elevated plasma levels of tissue plasminogen activator and occult cancer risk: a nested case-cohort analysis in 10,294 healthy subjects S. Bolognini1,2, C. Ticozzi1, P. Gomez-Rosas1,3, L. Russo1,2, Cj. Tartari1,2, F. Schieppati1,2, G. Sampietro4, L. Barcella1, M. Marchetti1,2, A. Falanga1,2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, The Netherlands; 4Unit of Epidemiology and Statistics, ATS Bergamo, Italy
710PDF: 43 -
PO57 | A NOVEL RISK ASSESSMENT MODEL FOR CANCER DETECTION WITHIN ONE YEAR AFTER INCIDENT VENOUS THROMBOEMBOLISM C. Antoun1, J. Hansen1|3, S. Brækkan1|3, C. Langholm1, N. Eide1, V. Morelli1|3, K. Hveem2 | 1Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø; 2HUNT Center for Molecular and Clinical Epidemiology, Norwegian University of Science and Technology, Trondheim; 3Thrombosis Research Center, Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
525PDF: 106 -
PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy
659PDF: 28 -
PO108 | DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH VENOUS THROMBOEMBOLISM RECEIVING LONG-TERM IMMUNOSUPPRESSIVE THERAPY AFTER LIVER AND KIDNEY TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE U. Mazzarelli1, L. Agrelli1, A. Cirillo1, C. Crescenzo2, M. Triggiani1, A. Guida3 | 1Dipartimento di Medicina Interna, Università degli studi di Salerno, Italy; 2UOC Nefrologia e Trapianti di rene; 3Centro per le malattie emorragiche congenite e malattie trombotiche, AOU San Giovanni di Dio e Ruggi d'Aragona Salerno, Italy
71PDF: 30 -
CO049 | RANDOMIZED CONTROLLED TRIAL TO IDENTIFY THE OPTIMAL SCHEME OF HEPARIN FOR TREATMENT OF DEEP VEIN THROMBOSIS IN PREGNANCY E. Grandone1|3, E. Antonucci2, A. de Laurenzo1, L. Latino1, M. Mastroianno1, G. Tiscia1, M. Margaglione3, P. Prandoni2 | 1IRCCS Casa Sollievo della Sofferenza, S.Giovanni Rotondo, Italy; 2Fondazione Arianna, Italy; 3Università di Foggia, Italy
71PDF: 33 -
OC09 | BLEEDING RISK ASSOCIATED WITH FACTOR XI MONOCLONAL ANTIBODIES IN COMBINATION WITH ASPIRIN IN HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY PATIENTS: ANALYSIS FROM RECENT PHASE 1 AND PHASE 2 STUDIES A.P. Kithcart1, M.E. Burczynski1, P. Banerjee1, M. Onisko1, Y. Wang1, K. Mohammadi1, D. Li1, S. Li1, J. Ackroyd2, B.A. Olenchock1, D.E. Gutstein1, J. I. Weitz3 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Clinical Research, Fortrea Clinical Research Unit Ltd, Leeds, UK; 3McMaster University, Hamilton, ON, Canada
466PDF: 123 -
PO76 | Thrombosis associated with midline in autoimmune patient: a case report on the use of apixaban in a real-world setting M.V. Cherchi, M. Anedda, S. Che, M. Vacca, M. Caboni, M. Mantega | Department of Internal Medicine, ASL Sulcis, Italy
616PDF: 36 -
CO074 | WHOLE-BLOOD COAGULATION AND PLATELET DYNAMICS IDENTIFY DIFFERENTIAL PROTHROMBOTIC STATES IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK OR TNFⱭ INHIBITORS L. Spiezia, A. Giollo, L. Di Luozzo, M. Salvato, K. Khalid, R. D’Andrea, A. Benetti, C. Samà, R. Ramonda, P. Simioni | Dipartimento di Medicina, Azienda Osp. Università di Padova, Italy
65PDF: 32 -
PO45 | KHORANA RISK SCORE AND GENOMIC PROFILING FOR PREDICTION OF VENOUS THROMBOEMBOLISM IN OVARIAN CANCER P. Santini, L. Mastrantoni, G. Anderson, F. Camarda, I. Marino, J. Preziosi, M. Buttarelli, M. Manfredelli, A. Minucci, F. Persiani, L. Giacò, T. Pasciuto, I. Conti, I. Mozzetta, F. Mancinetti, S. M. P. D’Ambrosio, M. Bigossi, C. Marchetti, V. Salutari, G. Scambia, C. Nero, R. Pola | Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy
472PDF: 119 -
PO077 | BALANCING BLEEDING AND THROMBOSIS: SAFETY OF LOW-MOLECULAR-WEIGHT HEPARIN THROMBOPROPHYLAXIS IN PATIENTS WITH HEMOPHILIA UNDERGOING MAJOR SURGERY S. Bergonzi1|2|3, G. Murante1|2|3, M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, A. Valpreda3|4, R. Pastorino3|4, F. Bocchi3|4, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, Università di Torino, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Università di Torino, Italy
49PDF: 26 -
PO56 | EXTERNAL VALIDATION OF THE SAVED SCORE IN A CANADIAN REGIONAL CANCER CENTER COHORT: A REAL-WORLD ANALYSIS A. Naassan, R. Fatima, M. Naassan, C. Chisholm | Lakeridge Health, R.S. McLaughlin Durham Regional Cancer Centre, Department of Oncology, Oshawa, ON, Canada
882PDF: 128 -
CO05 | Long-term management of upper extremity catheter-related thrombosis in female patients with cancer: a retrospective cohort study Chiara Cavallaro1,2, Paolo Santini1,2, Laura Leoni3, Carolina Mosoni1,2, Silvia D’Ambrosio1,2, Francesco Mancinetti1,2, Nicola Coletta1,2, Michela Iorio1,2, Angelo Porfidia1,2, Alessandro D’Errico1,2, Rosa Talerico1,2, Roberto Pola1,2 | 1Department of Aging, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; 2Università Cattolica del Sacro Cuore, Rome; 3Vita-Salute University, San Raffaele Hospital IRCCS, Milan, Italy
688PDF: 34 -
PO106 | INTERACTIONS BETWEEN DIRECT ORAL ANTICOAGULANTS AND ANTIEPILEPTIC DRUGS (INTER-DOAC): A PROSPECTIVE OBSERVATIONAL STUDY A. Rafanelli1, C. Pizzanelli3, M. Biagini1, P. Chiarugi4, M. Casini4, P. Capozza5, G. Guarini5, L. Malloggi4, G. Siciliano3, R. De Caterina5|6, L. Carrozzi1|2, F. Pistelli1|2, L. Marconi2, A. Celi1|2, R. Pancani2 | 1Pulmonary Division, Dep. of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy; 2Pulmonary Unit, Cardiothoracic and Vascular Dep., University Hospital of Pisa, Pisa, Italy; 3Neurology Unit, Dep. of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; 4Clinical Chemistry Laboratory, Dep. of Laboratory Medicine, University Hospital of Pisa, Pisa, Italy; 5Cardiology Unit, Cardiothoracic and Vascular Dep., University Hospital of Pisa, Pisa, Italy; 6Cardiology Division, Dep. of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy
48PDF: 25 -
CO048 | PREDICTORS OF FIRST THROMBOTIC EVENTS AFTER MECHANICAL VALVE REPLACEMENT FOR RHEUMATIC HEART DISEASE: A RETROSPECTIVE COHORT STUDY FROM SALAM CENTER FOR CARDIAC SURGERY (SUDAN) N. Erba1|3, S. Abdelwahab Abdallah1, D. Poli3, M. Langer2, G. Portella2, E. Giovanella1, F. Masini1, P. Malerba2 | 1The Salam Centre for Cardiac Surgery, Emergency NGO, Khartoum, Sudan; 2Emergency NGO Milano, Italy; 3Federazione dei Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Anti trombotiche, Italy
72PDF: 26 -
PO30 | LONG-TERM ANTICOAGULANT THERAPY AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM IN ADVANCED OVARIAN CANCER V. Bitsadze 1, A. Vorobev 1, J. Khizroeva 1, A. Solopova 1, M. Tretyakova 1, N. Gashimova 1, K. Grigoreva 1, A. Khisamieva 1, J. Gris 1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
484PDF: 101 -
OC06 | PRIMARY THROMBOPROPHYLAXIS IN ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA UNDERGOING SYSTEMIC ANTICANCER TREATMENT: A CANCER-CENTER COHORT STUDY ON CLINICAL PRACTICE AND OUTCOMES F. Haque1|2, A. Adekeye1|2, Z. Mohtashim2, K. Page1, M. Goodman1, A. Maraveyas 1|2 | 1Hull University Teaching Hospital NHS Trust, UK; 2Hull York Medical School, UK
499PDF: 112 -
PO124 | BLEEDING COMPLICATIONS DURING ANTICOAGULATION WITH DOACS FOR NVAF AND THEIR MOST COMMON RISK FACTORS A. delle Femine, P. Di Micco, P. Sommese, M. Di Napoli, A. Di Salvatore, M. Galdiero, A. Lobasso, R. Serpico, V. Brunelli, A. Di Fusco, C. di Gennaro | U.O.C. Medicina Interna, Osp. Santa Maria delle Grazie, Pozzuoli, Italy
45PDF: 22 -
CO064 | THROMBOTIC AND BLEEDING EVENTS IN PATIENTS WITH VASCULAR INVASION BY ADVANCED HEPATOCELLULAR CARCINOMA: A SYSTEMATIC REVIEW L. Leoni1, G. Tosti2, F.R. Ponziani2, A. Porfidia2, F. Landi2, A. Gasbarrini2, R. Pola2, F. Santopaolo2, R. Talerico2 | 1Internal Medicine Department, Vita-Salute San Raffaele University, IRCCS, Milano, Italy; 2Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy
67PDF: 23 -
PO44 | PREDICTORS OF ONE-YEAR MORTALITY IN NEWLY DIAGNOSED METASTATIC BREAST CANCER: THE PROGNOSTIC ROLE OF HEMOSTATIC BIOMARKERS AND EARLY THROMBOEMBOLISM M. Marchetti1|2|3, P. Gomez-Rosas1|4|5, S. Bolognini1, C. Ticozzi1, D. Romeo1, F. Schieppati1|3, L. Barcella1|3, F. Petrelli6, A. D'Alessio7, R. Labianca7, A. Falanga1|2|3 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 3ERN EuroBloodNet; 4Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; 5Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; 6Oncology Unit, Hospital Treviglio-Caravaggio, Treviglio, Italy; 7Fondazione ARTET Onlus, Bergamo, Italy; *On behalf of the Hypercan Investigators
491PDF: 111 -
PO18 | Does muscle mass matter? Appendicular lean mass as a determinant of anti-XA activity in elderly patientes B.M. Zanforlini1, V. Bernardi1, E. Campello2, E.M. Bicego1, C. Curreri1, A. Vaticano1, C. Sartori1, L. Manfron1, A. Perencin1, P. Rollo1, A. Baruffol1, L. Ruoso1, C. Simion2, C. Bulato2, P. Berto2, P. Simioni2, G. Sergi1 | 1Department of Medicine, Geriatrics Section, University of Padova; 2Haemorrhagic and Thrombotic Diseases Unit, Department of Medicine DIMED, Padova University Hospital, Padova, Italy
614PDF: 21 -
PO067 | LONG‑TERM SAFETY AND EFFECTIVENESS OF VITAMIN K ANTAGONISTS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES: A RETROSPECTIVE COHORT ANALYSIS G. Sottilotta1, G. Praticò1, D. Megalizzi1, F. Luise2 | 1UOSD Centro per le Microcitemie - Servizio Emostasi e Trombosi; 2Laboratorio Analisi, Grande Ospedale Metropolitano di Reggio Calabria, Italy
49PDF: 27 -
PO12 | IMPACT OF INHERITED THROMBOPHILIA ON CANCER-ASSOCIATED THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS E. Campello1, G. Furlan1, A. Boccatonda2, A. Napolitano1, C. Simion1, P. Simioni1 | 1Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy; 2Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy
494PDF: 117 -
PO94 | The use of antidepressant drugs and benzodiazepine hypnotics as an unusual risk factor for VTE G. Chiarelli, F. Strano, P. Conca, P. Rufolo, M. G. Mazzone, R. Russo, L. Jr Valletta, G. D’Errico, C. De Luca, E. Cimino, A. Tufano, M.N.D. Di Minno | Department of Clinical Medicine and Surgery, Federico II University of Naples, Italy
757PDF: 26 -
PO160 | THE USE OF ANTIDEPRESSANT DRUGS AND BENZODIAZEPINE HYPNOTICS AS AN UNUSUAL RISK FACTOR FOR VTE G. Chiarelli, C. Caputo, M. Romeo, F. Strano, P. Conca, P. Rufolo, M.G. Mazzone, R. Russo, L. Valletta Jr., G. D’Errico, C. De Luca, E. Cimino, A. Tufano | DMCC. "Federico II" University of Naples, Italy
80PDF: 37 -
PO105 | IMPACT OF ECOG PERFORMANCE STATUS ON CANCER-ASSOCIATED THROMBOSIS TREATED WITH DOACS: DATA FROM A MULTICENTER COHORT STUDY R. Talerico1, F. Mancinetti1, C. Sacco2, M. Mazzetti3, E. Campello4, S. Birocchi5, S. Beccatini6, A. Porfidia1, C. Lodigiani2, P. Simioni4, G.M. Podda5, I. Mastandrea2, C. Becattini6, R. Pola1, M.C. Vedovati6 | 1Thrombosis Unit, Department of Geriatric, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; 2Thrombosis and Hemorrhagic Diseases Unit, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 3Interdisciplinary Internal Medicine, Careggi University Hospital, Firenze, Italy; 4First Chair of Internal Medicine and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy; 5Medicine II Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milano, Milano, Italy; 6Internal, Vascular and Emergency Medicine– Stroke Unit, University of Perugia, Perugia, Italy
49PDF: 25 -
CO042 | BLEEDING RISK IN PATIENTS RECEIVING CONCURRENT TREATMENT WITH DIRECT ORAL ANTICOAGULANTS AND CORTICOSTEROIDS: A SYSTEMATIC REVIEW M.A. Capparella1, R. Talerico2, C. Cavallaro2, M. Iorio2, F. Bossi1, A. Porfidia2, K. Abe3, M. Biglietto4, A. Chistolini4, A. Holt5, L. Lahousse6|7, R. Pola2, C. Becattini1, M.C. Vedovati1 | 1Internal, Vascular and Emergency Medicine – Stroke Unit, University of Perugia, Italy; 2Thrombosis Unit, Department of Geriatric, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico A. Gemelli IRCCS, Roma, Italy; 3Division of Gastroenterology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan; 4Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma, Italy; 5Department of Cardiology, Copenhagen University Hospital – Herlev and Gentofte, Copenhagen, Denmark; 6Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium; 7Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
79PDF: 33 -
PO29 | CANADIAN INSIGHTS INTO THE MANAGEMENT OF BREAKTHROUGH THROMBOSIS S. Ramdani1, C. Séguin2 | 1Division of Hematology, Post-Graduate Medical Education Program, McGill University, Montreal; 2Division of Hematology, Department of Medicine, McGill University Health Center, Montreal, Canada
500PDF: 101 -
CO08 | The utility of urine qualitative assessment for direct oral anticoagulants in routine clinical practice F. Schieppati1,2, P. Gomez-Rosas1,3, C. Ambaglio1, V. Brusegan1, Oc. Cretu1,2, E. Galimberti1, F. Zunino1, L. Barcella1, J. Harenberg4,5, A. Falanga1,2, M. Marchetti1,2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Ruprecht Karls University of Heidelberg, Germany; 5Germany DOASENSE GmbH, Heidelberg, Germany
761PDF: 29 -
PO004 | SEX-RELATED DIFFERENCES AND PREDICTORS OF MORTALITY IN MAJOR ORTHOPEDIC SURGERY: INSIGHTS FROM THE ORTHO-START REGISTRY A. de Laurenzo1, E. Antonucci2, C. Rostagno3, D. Barcellona4, D. Colaizzo1, G. di Rienzo5, F. Gorgoglione1, G. Maccagnano6, F. Marongiu2, M. Mastroianno1, M. Marzolo7, L. Mirabella6, B. Moretti8, A.M. Moretti9, A. Ostuni6, G. Palareti2, M. Margaglione6, E. Grandone1|6 | 1Fondazione I.R.C.C.S. “Casa Sollievo della Sofferenza”, S. Giovanni R. (Foggia), Italy; 2Fondazione Arianna, Bologna, Italy; 3Department of Internal and Postoperative Medicine, Careggi University Hospital, Firenze, Italy; 4Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; 5UOC Patologia Clinica-Ospedale Altamura ASL Bari, Italy; 6University of Foggia, Policlinico Riuniti Foggia, Italy; 7Angiology Unit, Ospedale di Rovigo, Rovigo, Italy; 8School of Medicine, AOU Consorziale Policlinico, University of Bari "Aldo Moro", Italy; 9President of GISeG (Italian Group for Health and Gender), Bari, Italy
48PDF: 24 -
Whole exome sequencing in a family with thromboangiitis obliterans
1139PDF: 137SUPPLEMENTARY FILES: 105 -
OC02 | INCIDENCE AND PREDICTORS OF ARTERIAL THROMBOSIS IN CANCER PATIENTS: RESULTS FROM THE PROSPECTIVE COMPASS-ARTERIAL CANCER ASSOCIATED THROMBOSIS (COMPASS-ARTECAT) STUDY M. Drakopoulou1, I. Diamandoulaki2, P. Baglaridis1, P. Las Casa3, P. Van Dreden4, K. Toutouzas1, G. Gerotziafas4|5 | 1First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece; 2Department of Electrical and Computer Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris France; 4Diagnostica Stago, clinical research, Gennevilliers, France; 5Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA
527PDF: 136 -
PO70 | Clinical safety and monitoring of apixaban combined with tacrolimus and everolimus in kidney transplant patients: a prospective study S. Guglielmo1, E. De Bon2, L. Scarano1, R. Fabris1, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 3Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padova, Italy
652PDF: 36 -
CO062 | REDUCED-DOSE DOACs IN EXTENDED TREATMENT OF CANCER-ASSOCIATED THROMBOSIS (RED-CAT): INTERIM ANALYSIS FROM A MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY (COORDINATING CENTER DATA) S. Bergonzi1|2|3, A. Ghigo4, L. Carpisassi4, G. Murante1|2|3, M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, A. Valpreda3|5, R. Pastorino3|5, F. Bocchi3|5, A. Porreca6|7, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, Università di Torino, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Division of Internal Medicine, AOU Città della Salute e della Scienza, Università di Torino, Italy; 5Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Università di Torino, Italy; 6Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Roma, Italy; 7Clinical and Molecular Epidemiology, IRCCS San Raffaele, Roma, Italy
54PDF: 32 -
PO011 | A TWO CENTERS REAL-WORLD EXPERIENCE WITH ANTI-XA DIRECT ORAL ANTICOAGULANTS IN CANCER PATIENTS WITH UNUSUAL SITE VEIN THROMBOSIS U. Mazzarelli1, L. Agrelli1, A. Cirillo1, C. Caputo2, M. Romano2, R. Russo2, R. Guarrasi3, M. Triggiani1, A. Tufano2, A. Guida4 | 1Dipartimento di Medicina Interna, Università degli studi di Salerno, Italy; 2Dipartimento di Medicina Interna, Università degli studi di Napoli Federico II, Italy; 3UOC Clinica Oncologica; 4Centro per le malattie emorragiche congenite e malattie trombotiche AOU San Giovanni di Dio e Ruggi d'Aragona Salerno, Italy
68PDF: 30 -
PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL R.A.L. Willems1|5, A.E. Van Diepen1|2|6, EN. Dekker7, Q.P. Janssen7, J.L. Van Dam7, N. Michiels8, C.W.F. Van Eijck9, K.E.P.E. Hermans1|2, B.A. Bonsing8, K.P. Bosscha10, S.A.W. Bouwense11|12, O. R. Busch13|14, H. Ten Cate4|5|15|16, P.P.L.O. Coene17, C.H.J. Van Eijck7, N. Van Es18|19, E. Van Der Harst17, I.H.J.T. De Hingh20, T.M. Karsten21, G. Kazemier13|14, M.B. Van Der Kolk22, B. De Laat3|5, M.S.L. Liem22, J.S.D. Mieog8, V.B. Nieuwenhuijs24, G.A. Patijn24, M. Roest3, H.C. Van Santvoort25, L. Valkenburg-Van Iersel1|2, R. F. De Wilde7, F. Wit26, B.M. Zonderhuis13|14, M.G. Besselink13|14, M.Y.V. Homs6, G. Van Tienhoven14|27, J. W. Wilmink14|28, B. Groot Koerkamp7, J. De Vos-Geelen1|2 | 1Maastricht University Medical Center, Department of Internal Medicine, Division of Medical Oncology; 2GROW – Research Institute for Oncology & Reproduction, Maastricht University, Maastricht; 3Synapse Research Institute, Department of Functional Coagulation, Maastricht; 4Maastricht University Medical Center, Thrombosis Expert Center Maastricht, Maastricht; 5Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht; 6Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam; 7Erasmus MC Cancer Institute Rotterdam, University Medical Center Rotterdam, Department of Surgery; 8Leiden University Medical Center, Department of Surgery, Leiden; 9Solid Tumour Immunology Research Rotterdam (STIRR), Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam; 10Jeroen Bosch Hospital, Department of Surgery, Den Bosch; 11Maastricht University Medical Center, Department of Surgery, Maastricht; 12Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht; 13Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam; 14Cancer Center Amsterdam; 15Maastricht University Medical Center, Department of Internal Medicine, Division Vascular Medicine, Maastricht; 16Maastricht University, Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht; 17Maasstad Hospital, Department of Surgery, Rotterdam; 18Amsterdam UMC, location University of Amsterdam, Department of Vascular Medicine, Amsterdam; 19Amsterdam UMC, location University of Amsterdam, Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam; 20Catharina Hospital, Department of Surgery, Eindhoven; 21OLVG, Department of Surgery, Amsterdam; 22Radboud University Medical Center, Department of Surgery, Nijmegen; 23Medisch Spectrum Twente, Department of Surgery, Enschede; 24Isala Oncology Center, Department of Surgery, Zwolle; 25Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Department of Surgery, Utrecht; 26Frisius MC, location Leeuwarden, Department of Surgery, Leeuwarden; 27Amsterdam UMC, location University of Amsterdam, Department of Radiation Oncology, Amsterdam; 28Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands
454PDF: 99 -
PO93 | Use of DOACS in heart transplantation recipients T. Marrazzo1, A. Delle Femine1, C. Amarelli2, R. Albisinni3 | 1UOC Medicina Interna e dei Trapianti, Ospedale Monaldi Azienda dei Colli, Napoli; 2UOSD CCH dei Trapianti, Ospedale Monaldi Azienda dei Colli, Napoli; 3UOC CCH Generale, Ospedale Monaldi Azienda dei Colli, Napoli, Italy
761PDF: 23 -
CS01 | Elucidating the evil relationship of metabolic dysfunction–associated fatty liver disease with cardiovascular comorbidities: the complex interplay among hypercoagulability, inflammation and liver fibrosis G. Gagliardi, E. Campello, A. Napolitano, B. Stocco, C. Di Gesù, G. Gobbo, I. Condonato, M. Allegra, G. Camporese, P. Scarinzi, R. Pesavento, F. Bilora, C. Bulato, A. Benetti, C. Samà, C. Portinari, G. Antonello, C. Goffi, L. Di Daniel, A. Zambon, L. Fabris, P. Simioni | First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
836PDF: 27 -
PO156 | DIRECT ORAL ANTICOAGULANTS FOR THE TREATMENT OF VTE IN PATIENTS WITH CANCER: A SURVEY AMONG CAMPANIAN INTERNAL MEDICINE WARDS E. Marrone1, C. Arturo2, F. Cannavacciulo3, D. D’Ambrosio4, F. Gallucci1, M. Amitrano3, C. Di Gennaro2, P. Morella1, A. Maffettone5 | 1UOC Medicina 3, AORN A Cardarelli, Napoli, Italy; 2UOC Medicina Generale, PO A. Rizzoli, Ischia, Italy; 3UOC Medicina Interna, AO Moscati, Avellino, Italy; 4UOC Medicina Generale, PO Piedimonte Matese ASL Caserta, Italy; 5UOC Medicina interna, PO San Luca, Vallo Della Lucania ASL Salerno, Italy
50PDF: 27 -
PO37 | Single centre experience on anticoagulation in carriers of non-mild inherited thrombophilia: direct oral anticoagulants (DOAC) efficacy and safety M. D’uva1,2, G. La Barba1, G. Montanaro1, M. Di Ianni1,2, P. Ranalli1,2 | 1Hematology Unit, S. Spirito Hospital, Pescara; 2Department of Medicine and Aging Sciences, D’Annunzio University, Chieti, Italy
666PDF: 32 -
PO104 | BLEEDING AND THROMBOTIC OUTCOMES DURING EXTENDED DIRECT ORAL ANTICOAGULANT THERAPY: AN EIGHT YEAR RETROSPECTIVE ANALYSIS G. Sottilotta1, G. Praticò1, S. Cuzzocrea1, D. Megalizzi1, F. Luise2 | 1UOSD Microcitemie - Emostasi e Trombosi. Grande Ospedale Metropolitano di Reggio Calabria, Italy; 2Laboratorio Analisi. Grande Ospedale Metropolitano di Reggio Calabria, Italy
69PDF: 27 -
CO039 | CLINICAL SAFETY AND MONITORING OF APIXABAN IN HEMODIALYSIS PATIENTS: A PROSPECTIVE STUDY S. Guglielmo1, M. Lovisotto1, E. De Bon2, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine; 2Thrombosis and Haemostasis Unit, Department of Medicine; 3Nephrology and Dialysis Unit, Azienda Ulss 6 Euganea, Cittadella and Camposampiero, Padova, Italy
103PDF: 25 -
PO27 | URINE QUALITATIVE ASSESSMENT OF DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE F. Schieppati1|2, P. Gomez-Rosas1|3, C. Ambaglio1, V. Brusegan1, O.C. Cretu1, E. Galimberti1, F. Zunino1, L. Barcella1, J. Harenberg4|5, A. Falanga1|2, M. Marchetti1|2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Ruprecht Karls University of Heidelberg, Heidelberg, Germany; 5DOASENSE GmbH, Heidelberg, Germany
467PDF: 100 -
CO06 | Recurrences of catheter associated upper extremity deep vein thrombosis in cancer: a two year prospective study with enoxaparin M. Sartori, A. Trentini, S. Cavara, L. Borgese, M. Soldati, B. Cosmi | Angiology and Blood Coagulation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
692PDF: 36 -
PO003 | CATHETER-RELATED THROMBOSIS IN CANCER PATIENTS: A RETROSPECTIVE REAL-WORLD STUDY G. Autiero1|3, S.A. Malerba1|2|4, F. Busato1|2, D. Tolomio1|2, M. Dalla Vestra1|2, F. Presotto1|2 | 1U.O. Medicina Generale, Osp. Dell'Angelo, Venezia-Mestre, Italy; 2U.O. Angiologia, Osp. Dell'Angelo, Venezia-Mestre, Italy; 3Dip. Medicina Interna, Università degli Studi di Padova, Italy; 4U.O.C. Medicina Generale ad indirizzo trombotico ed emorragico, Università degli studi di Padova, Italy
45PDF: 26 -
PO61 | ACTN1-related thrombocytopenia and severe hyperhomocysteinemia: a case report A. Pozzi, G. Rosati, M. Padrini, S. Laurenti, G. Ferrari, R.M. Medici, C. Barale, I. Russo, A. Morotti | University of Turin, San Luigi Hospital, Orbassano (TO), Italy
583PDF: 25 -
PO08 | Efficacy and safety of thromboprophylaxis in hospitalized hematological patients: a monocenter retrospective study S. Cordella1,2, V. Coluccio3, M. Luppi1, M. Marietta1 | 1Department of Medical and Surgical Sciences, Section of Hematology. University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena; 2Clinical and Experimental Medicine PhD Programme, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena; 3Department of Hematology, Unità Sanitaria Locale di Modena, Italy
590PDF: 21 -
PO010 | D-DIMER TESTING BEYOND THROMBOSIS: A LABORATORY AUDIT OF TEST UTILIZATION, APPROPRIATENESS AND INTERPRETIVE CHALLENGES A. Mameli1, E. Casula2, E. Poma2, F. Marongiu1, D. Barcellona1 | 1Haemostasis and Thrombosis Unit; 2Laboratory Clinical Chemical Analysis and Microbiology, Azienda Ospedaliero-Universitaria (A.O.U.), Cagliari, Italy
65PDF: 23 -
CO007 | TPO-RECEPTOR AGONISTS AS AN INDEPENDENT RISK FACTOR FOR VENOUS THROMBOTIC EVENT IN IMMUNE THROMBOCYTOPENIA PATIENTS WITH PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES POSITIVITY M. Biglietto, B. Mandelli, S. Sorella, S. Ligia, C. Andriola, R. Mormile, E. Baldacci, A. Chistolini, S. Truglia, C. Santoro | Sapienza, University of Rome, Italy
166PDF: 27 -
PO92 | Challenging management of portal vein thrombosis in a cirrhotic patient on hormone therapy after breast cancer L. Jr Valletta, C. De Luca, M. Aversano, C. Caputo, E. Cimino, P. Conca, A. Tufano, M.D. Di Minno | AOU Federico II Napoli, Italy
581PDF: 25 -
PO155 | MANAGEMENT OF ANTICOAGULANT THERAPY IN IMMUNOTHROMBOSIS SECONDARY TO TOXOPLASMA INFECTION A. Grembiale1, A. Sabena1, G. Dettori1, C. Grendene1, S. Grazioli1, S. Venturini2 | 1SOC Medicina Interna 2 - Azienda Sanitaria Friuli Occidentale - Pordenone, Italy; 2SSD Malattie Infettive - Azienda Sanitaria Friuli Occidentale - Pordenone, Italy
68PDF: 32 -
CO087 | PLATELET ACTIVATION AND THROMBOSIS IN PATIENTS WITH FACTOR V LEIDEN MUTATION: A CROSS-SECTIONAL STUDY V. Cammisotto1, E. Valeriani2, S. Bartimoccia1, V. Castellani1, A. Pannunzio3, I. Palumbo3, C. Nocella1, R. Carnevale4, F. Violi1, P. Pignatelli1 | 1Department of Medical and Cardiovascular Sciences, Sapienza University of Roma, Italy; 2Department of Infectious Disease, AOU Policlinico Umberto I, Roma, Italy; 3Department of General Surgery and Surgical Speciality, Sapienza University of Roma, Italy; 4Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Roma, Italy
60PDF: 27 -
PO35 | Cerebral veins thrombosis in patients with and without myeloproliferative neoplasm: a real life retrospective monocentric study I. Bertozzi, M.T. Sartori, M. Zerbinati, G. Libralon, A. Galbiati, P. Simioni | First Medical Clinic, Department of Medicine - DIMED, Università degli Studi di Padova, Italy
615PDF: 36 -
PO103 | THE EFFECT OF ALBUMIN ON SERUM CONCENTRATION OF DIRECT ORAL ANTICOAGULANTS: A CROSS-SECTIONAL STUDY A. Pannunzio1, E. Valeriani2, I.M. Palumbo1, V. Cammisotto3, S. Bartimoccia3, V. Castellani3, S. Marucci3, D. Pastori3, D. Menichelli3, P. Pignatelli3 | 1Dip. di Chirurgia generale, specialistica ed anestesiologia - Università degli studi di Roma La Sapienza, Italy; 2Dip. di Medicina Interna, Scienze Endocrino-metaboliche e Malattie Infettive - Università degli Studi di Roma La Sapienza, Italy; 3Dip. di Medicina e Scienze Cardiovascolari - Università degli Studi di Roma La Sapienza, Italy
47PDF: 24 -
PO25 | EVOLUTION OF ANTICOAGULANT STRATEGIES AND CLINICAL OUTCOMES IN CANCER-ASSOCIATED THROMBOSIS: A LONGITUDINAL ANALYSIS OF THE START2 REGISTRY ONCO-VTE M. Marchetti1|2, T. Zollner1|2, OC. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Turin, Italy; 7Department of Medicine, University of Padua, Padua, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Rome, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
451PDF: 95 -
PO48 | Thrombotic risk evaluation and thrombophilia testing in β-thalassemia patients: a retrospective cohort analysis from a reference regional center G.M. Camarda1,2*, S. Raso1*, R. Di Maggio1, M. Vinciguerra3, A. Giangreco1, A. Inzerillo1, A. Maggio, M. Napolitano1,2 | *These authors contributed equally to this abstract; 1Hematology and Rare Diseases Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo; 2Division of Hematology Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “ProMISE”, Palermo; 3UOSD Molecular Diagnosis of Rare Blood Diseases, Azienda Ospedaliera, Ospedali Riuniti Villa Sofia, Cervello, Palermo, Italy
673PDF: 39 -
CO051 | PROTEIN S HEERLEN AND OTHER PROS1 GENE VARIANTS IN PROTEIN S-DEFICIENT PATIENTS: A SINGLE-CENTER STUDY F. Ramundo, T. Malara, M. Rossi, T. Za, AM. Ciminello, S. Betti, F. Bartolomei, F. Di Landro, P. Arcuri, P. Chiusolo, V. De Stefano, E. Rossi | Catholic University, Fondazione Policlinico A.Gemelli IRCCS, Italy
80PDF: 34 -
PO009 | THROMBOPHILIA AND ASSISTED REPRODUCTIVE TECHNOLOGY: PRELIMINARY RESULTS FROM A SINGLE CENTER RETROSPECTIVE COHORT STUDY G. Burrei2, E. Malloggi1, S. Moruzzi1, L. Delfino1, F. Pizzolo1, L. Panepinto1, F. Presa1, C. Spillere1, A. Moschella1, F. Zoccatelli1, S. Friso1, N. Martinelli1, S. Suardi1 | 1Department of Medicine, University Hospital, Verona, Italy; 2General Medicine Unit, Magalini Hospital, Villafranca di Verona, Italy
78PDF: 28 -
CO-66 | PREGNANCY OUTCOMES AND PERIPARTUM MANAGEMENT IN WOMEN WITH CONGENITAL FIBRINOGEN DISORDERS: A SINGLE-CENTRE EXPERIENCE T. Martini1, B. Borsellino1|2, B. Pollio1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy
70PDF: 22
